Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells

Journal of Nephrology

Volumn 28, Issue 4, 2015, Pages 431-440

  Zaza, Gianluigi ^a   Masola, Valentina ^a   Granata, Simona ^a   Bellin, Gloria ^a   Dalla Gassa, Alessandra ^a   Onisto, Maurizio ^b   Gambaro, Giovanni ^c   Lupo, Antonio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Epithelial mesenchymal transition; Everolimus; Fibrosis; mTOR; Sulodexide; Tubular cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLOSPORIN; EVEROLIMUS; FIBRONECTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; SULODEXIDE; VIMENTIN; ACTA2 PROTEIN, HUMAN; ACTIN; GLYCOSAMINOGLYCAN; MESSENGER RNA; PROTECTIVE AGENT;

ACUTE GRAFT REJECTION; ARTICLE; CELL GROWTH; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REOXYGENATION; UPREGULATION; WESTERN BLOTTING; CELL HYPOXIA; CELL LINE; CELL PROTECTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; EPITHELIUM CELL; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY PROXIMAL TUBULE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME FACTOR;

ACTINS; CELL HYPOXIA; CELL LINE; CYTOPROTECTION; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EVEROLIMUS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY TUBULES, PROXIMAL; PHOSPHORYLATION; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TIME FACTORS;

EID: 84937434833     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0216-y     Document Type: Article

References (51)

1. Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T (2012) New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 8(6):339–347
2. Kwiatkowski A, Wszoła M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Fesołowicz S, Michalak G, Trzebicki J, Durlik M, Paczek L, Rowiński W, Chmura A (2009) The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 14:14–17
3. Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group (2012) Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 366(8):770–771
4. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6:1111–1131
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kapplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378–383
6. US Renal Data System, USRDS (2013) Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013
7. Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611
8. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333
9. Chapman JR, O’Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16(10):3015–3026
10. Paul LC (1999) Chronic allograft nephropathy: an update. Kidney Int 56:783–793
11. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 117:524–529
12. Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116
13. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5:1367–1374
14. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC (2006) Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937–2946
15. Opelz G, Döhler B (2007) Multicenter analysis of kidney preservation. Transplantation 83:247
16. Hernández D, Estupiñán S, Pérez G, Rufino M, González-Posada JM, Luis D, Delgado P, Rodríguez A, Marrero D, Porrini E, Torres A (2008) Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant Int 21(10):955–962
17. Salahudeen AK, Haider N, May W (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 65(2):713–718
18. Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Compr Physiol 2(2):1303–1353
19. Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85:125–134
20. Geissler EK, Schlitt HJ (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78(11):1075–1079
21. Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626
22. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213
23. Masola V, Zaza G, Gambaro G (2014) Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i74–i79
24. Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11:292
25. Kosieradzki M, Rowiński W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288
26. van der Vliet JA, Warlé MC (2013) The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 18(2):174–178
27. Ponticelli C (2014) Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29(6):1134–1140
28. Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520
29. Perico N, Cattaneo D, Sayegh MH, Remuzzi G (2004) Delayed graft function in kidney transplantation. Lancet 364(9447):1814–1827
30. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M (2004) Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880
31. Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, van der Woude FJ, Yard BA, Braun C (2007) Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int 20(6):542–549
32. Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H (2012) Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 7:123
33. Zhou T, Chen JL, Song W, Wang F, Zhang MJ, Ni PH, Geng JG (2002) Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 8(5):897–900
34. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group, Sirolimus CONVERT Trial Study Group (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233
35. Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008) Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 22:366
36. Budde K, Becker T, Sommerer C et al (2009) Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 9:259 (Abstract 237)
37. Weir M, Mulgaonkar S, Pearson T et al (2009) Mycophenolatemofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 9:200 (Abstract 33)
38. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115
39. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837–847
40. Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328
41. Pallet N, Legendre C (2013) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12(2):177–186
42. Lieberthal W, Fuhro R, Andry CC (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706
43. Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC (2009) Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 22:681–687
44. Dantal J, Berthoux F, Moal MC (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-months results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093
45. Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280
46. Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A (2014) mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 5:495
47. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8(4):742–753
48. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940
49. Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12(4):487–502
50. Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864
51. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664